November 11, 2026 |

Sell Don���t Hype

By Anna Leah

When Kevin Gardner grew up in Cupertino, California, he delivered newspapers for San Jose Mercury News. Apricot orchards and grain silos still stood at the town���s main intersection. Technology companies have since changed the face of the city. Apple���s headquarters, not apricot skins, glint in the sunshine.

Now, hanging in at The City College of New York are some early, handwritten experimental data from his lab, professional awards, and an invitation to a barbecue kicking off his Texas company.

Gardner put his shoulder behind two biochemistry start-ups ��� both focused on novel ways to explore and fight cancer. While the did not take off commercially, the did.

Through 勛圖弝け���s (ASRC) and beyond, Gardner advises start-ups and people curious about them. He likes that the ASRC���s facilities aren���t just for him and his experiments, but for many people who might not be able to afford multi-million-dollar equipment.

He calls that environment a good reminder about entrepreneurship���s fun parts ��� allowing potential companies to jump into research with both feet. But he says that working in private industry can challenge academics.

Academic research can slowly grow from findings, and success is reflected by publications. Investors look for a clear line to an actionable answer. For that, researchers need to be critical about ���what do you really know, what do you think you know, what are you speculating or feeling,��� says Gardner. ���Those are three different categories, and you need to be crystal clear in your own mind and how you communicate this to others.���

Similarly, academic proposals might include a small paragraph in a 20-page proposal that asks the question, ���What if this succeeded?��� Collaborating with a private company, that question becomes all-important.

At the same time, Gardner warns potential pitchers about overselling to companies. He would never tell someone that his new idea could cure cancer when it is still in early research.

Gardner calls it a fine line between being excited about an idea and presenting the caveats the way scientists habitually do. ���Honesty is at the heart of it,��� says Gardner. ���The worst thing you can do is overhype something, have someone give you money, and a year later they���re walking away from the experience feeling jaded. That will follow you.���

His successful venture, Peloton Therapeutics, relied on several hundred million dollars in venture capital before Merck bought it for over $2 billion.

Gardner says success requires balancing chances. ���You don���t take risk, you gain nothing,��� he says. ���You take too much risk, you gain nothing.��� He says that every day a company���s doors are open, its funding gets smaller. He thinks researchers should move faster ��� even if a company only operates for one year, it might get more done if it works more aggressively earlier.

Commercial success also relies on an element of chance, he believes. If the industry recently tried something similar, if the market doesn���t break a certain way, if it���s a tight budget year, a researcher could be out of luck.

But, Gardner points out, public funds also help get a project to the place where it is ready for investment. He adds, ���I can only do what I do because at the end of the day those companies all start up with crazy ideas and funding by the NIH and NSF.���